The Voice of the Patient: Primary Sclerosing Cholangitis (PSC)

Report of an Externally-Led Patient-Focused Drug Development Meeting

Hosted by PSC Partners Seeking a Cure

Public Meeting: October 23, 2020
Report Date: April 11, 2022
The Voice of the Patient Report
Primary Sclerosing Cholangitis
Meeting Date: October 23, 2020
Report Date: April 11, 2022

This report has been prepared by PSC Partners Seeking a Cure (PSC Partners) as a summary of the input shared by patients living with primary sclerosing cholangitis (PSC) and their caregivers during an externally-led Patient-Focused Drug Development (PFDD) meeting hosted by PSC Partners on October 23, 2020. This report presents perspectives shared by the individuals who participated in the meeting and/or associated patient engagement activities. Participant input has been summarized by the authors to faithfully represent the comments and themes that emerged. This report does not represent any consensus among participants or the broader population of those living with PSC and does not include all possible perspectives.

Authors

Prepared and submitted on behalf of PSC Partners Seeking a Cure by:
Joanne Hatchett, RN, MS, FNP-retired, Medical Science Liaison, PSC Partners Seeking a Cure
Ricky Safer, Founder and CEO, PSC Partners Seeking a Cure
Rachel Gomel, Registry Director and Coordinator, PSC Partners Seeking a Cure
Mary Vyas, President, PSC Partners Seeking a Cure Canada, a PSC Partners affiliate
Meegan Carey, Executive Director, PSC Partners Seeking a Cure

Consultant

Assistance with writing the report was provided by Theresa Wizemann, PhD, under contract with PSC Partners Seeking a Cure.

Disclosures

The individuals listed above have nothing to disclose. The convening of this meeting by PSC Partners Seeking a Cure was supported solely by generous donations from the PSC Partners community of patients, families, caregivers, and friends.

Version and Permissions

This document has not been revised and/or modified after the report date listed above. PSC Partners Seeking a Cure has obtained all necessary permissions to submit this external resource to the FDA. Linking to this resource from the FDA website does not violate the proprietary rights of others.

Contact

For questions related to this resource, please contact PSC Partners at contactus@pscpartners.org.
ACKNOWLEDGEMENTS

PSC Partners Seeking a Cure is sincerely grateful to the PSC patients and caregivers who opened their hearts and courageously shared their very personal, and often painful stories of living with PSC. We appreciate the willingness of the speakers, panelists, and attendees to be open and honest about how PSC has impacted their lives. We are also truly grateful to the supportive and tight-knit PSC community, whose generous donations funded the production of this externally-led PFDD meeting. Sincere thanks to William Lewallen of FDA, for his guidance throughout the meeting planning process, and to Ruby Mehta, MD, of FDA, for her opening remarks on behalf of the FDA Patient-Focused Drug Development Program. PSC Partners is also very grateful to Christopher Bowlus, MD, and Jorge Bezerra, MD, for sharing their clinical expertise and providing the opening remarks about PSC disease and treatments that set the stage for the discussions. Special thanks to Veronica Miller, PhD, and Mary Vyas, President of PSC Partners Seeking a Cure Canada, for moderating and facilitating this PFDD meeting, and to John, Kyle, and Eric at Dudley Digital Works for producing a seamless virtual meeting. Thank you, Joanne Hatchett, for your sleepless nights and incredible attention to detail. Thank you to team members, Mary Vyas, Rachel Gomel, Meegan Carey, and Jen Chavez. And to Joanne Grieme, Katherine Schultz, and Raquel Valerio.

Finally, a heartfelt thank you to everyone who participated virtually in this PFDD meeting, including staff from FDA, academic and industry researchers, health care providers, rare disease advocates, and especially the PSC community of patients, families, caregivers, and friends who are the core of the program.

“Together in The Fight, Whatever It Takes!”

Ricky Safer
Founder and CEO
PSC Partners Seeking a Cure
ABOUT PSC PARTNERS SEEKING A CURE

PSC Partners Seeking a Cure – Ricky’s Story

Ricky Safer was a self-described “health, nutrition, and exercise fanatic” before she was diagnosed with PSC in March of 2004. Her “unpredictable and unrelenting journey with PSC” began in the emergency room where she was told she was having a cholangitis attack. She felt “utter fear” upon learning that PSC was rare, progressive, incurable, and potentially fatal, and that the only treatment was a liver transplant after which PSC might still reoccur. Forced to re-envision and redefine her life, she found that reliable information and support for PSC patients was woefully inadequate. With the help of her family and several other PSC patients, Safer founded PSC Partners Seeking a Cure and organized its first PSC conference in 2005. In 2015, an affiliate organization, PSC Partners Seeking a Cure Canada, was established by several parents of PSC patients.

The mission of PSC Partners Seeking a Cure is to drive research to identify treatments and a cure for PSC, while providing education and support for those impacted by this rare disease. “Every day I am made more aware of the complex and idiopathic disease that I am afflicted with,” Safer said. This externally-led PFDD meeting is the culmination of years of developing special programs and national and international collaborations, and has allowed PSC patients to share the burdens and challenges they face every day, and to provide input on the critical unmet need for treatments and, ultimately, a cure for PSC.

PSC Partners Seeking a Cure is a 501(c)(3) nonprofit organization. For more information visit pscpartners.org.
Primary sclerosing cholangitis (PSC) is a rare, progressive liver disease that is estimated to affect around 30,000 children and adults in the United States. Chronic inflammation and fibrosis of the bile ducts of the liver can block the flow of bile, leading to liver damage. Patients with end-stage liver disease or multiple infections of the bile ducts (cholangitis) often require liver transplantation. PSC has also been associated with an increased risk of developing life-threatening cholangiocarcinoma (cancer of the bile ducts), colon cancer, and gallbladder cancer. There is still much that is unknown about the origins and mechanisms of PSC. It appears that PSC is immune-mediated and is associated with both genetic and environmental factors, and there is a strong association between PSC and inflammatory bowel disease (IBD). There are currently no treatments for PSC that have been proven to slow the progression or alter the course of the disease. The only treatment known to improve survival for PSC patients is liver transplantation, but PSC can recur in about 25% of transplanted livers.

On October 23, 2020, PSC Partners Seeking a Cure hosted an interactive virtual public meeting giving patients and caregivers a unique opportunity to share how PSC has impacted their lives. They shared their first-hand experiences with existing treatments and their unique perspectives on the unmet treatment needs of PSC patients. The meeting was developed in conjunction with the U.S. Food and Drug Administration (FDA) as an externally-led Patient-Focused Drug Development (PFDD) meeting, to complement FDA’s PFDD initiative. The patient input collected at the meeting and reported here will have a lasting impact on the lives of PSC patients as it will inform the development and regulatory review of new drugs for this rare disease.

**KEY MESSAGES FROM THE PSC PARTNERS’ EXTERNALLY-LED PFDD MEETING**

*The Symptoms and Daily Impact of PSC that Matter Most to Patients*

- **PSC Symptoms That Most Impact Patients’ Lives**
  - **Fatigue** – extreme, different from being tired, not remedied by sleep
  - **Pruritus** – unrelenting, uncontrollable itch; often painful, interrupts sleep and slows down or prevents all routine activities
  - **Pain** – chronic, often does not improve with medication, impacts daily life, (abdominal, liver, joint, generalized)
  - **Impaired cognitive function** – “brain fog,” loss of identity, memory gaps, inability to function independently
Mental and emotional health issues – anxiety, depression, post-traumatic stress disorder (PTSD); significant concern for children and young adults with PSC; emotions can intensify physical symptoms

Other symptoms of concern – insomnia, varices/bleeding varices (enlarged or swollen veins in the esophagus [the tube connecting the throat to the stomach]), loss of appetite/weight loss, nausea/vomiting, as well as the consequences of osteopenia/osteoporosis (bone loss)

- Impact of PSC Clinical Symptoms on Quality of Life

  Unpredictability of PSC disease and the loss of opportunity – “missing out on life,” not being able to attend school, participate in activities and social events, continue a career, maintain a relationship, start a family; the loss of one’s childhood

  Uncertainty about the future - fears of needing a transplant, of not being able to get a transplant, of developing cholangiocarcinoma, of recurrent PSC after transplant, of loss of independence; balancing fear and hope while facing a lack of effective treatments

  Stress on relationships – partners, families, friends, school/work, support systems

  Lack of public understanding of PSC – the challenges of living with a disease that is often invisible, the social stigma associated with visible PSC symptoms; social stigma and bullying can be particular problems for children and adolescents with PSC

  Accessing care – concerns about the MELD scoring system for transplant prioritization, obtaining insurance coverage as a high-risk patient, extensive travel or relocation in pursuit of quality PSC care, transplant, or clinical trial participation

Priority Unmet Needs:

- Much remains unknown about the root causes and disease pathogenesis of PSC. A better understanding is needed of the clinical course of PSC, and the impact of pediatric PSC on growth and development. The true epidemiology of the disease is also not yet fully understood, due in part to the history of PSC not having an ICD-10 code until recently.

- Patients urgently need effective treatments for the symptoms of PSC. The extent, severity, and impact of the symptoms of PSC are still not well-characterized. There are no proven therapies to improve how PSC patients feel and function. Participants vividly described the significant impacts of pruritus, fatigue, and pain, in particular, on their ability to function on a daily basis and on their overall quality of life. Some turn to off-label use of existing medications (e.g., ursodiol, vancomycin) and further studies are needed on the role of these drugs in symptom and/or disease management.

- Transplant is not a cure. Liver transplantation is a high-risk procedure with the potential for serious complications and recurrence of PSC. A true medical cure for PSC is needed.

- More effective screening for early detection of cholangiocarcinoma is needed. Current tools for hepatobiliary cancer surveillance are of low sensitivity and do not identify disease in the early stages when intervention could increase survival.
• **Patients urgently need effective treatments for PSC.** No treatment has been proven to increase survival of PSC patients. Treatments are needed that slow PSC disease progression, delay the need for transplant, and prevent post-transplant recurrence of PSC.

• **Earlier and more efficient diagnosis of PSC is needed.** For many, the journey to diagnosis can be long and complicated. Patients also want less invasive methods for risk prediction and prognosis. There is a need to raise awareness of PSC symptoms among providers in general, and to educate providers who treat patients with IBD about the relationship between PSC and IBD.

**Taking the Next Steps Together:**

• **PSC Patients are ready and willing to participate in the search for treatments and a cure.** PSC patients are interested in participating in clinical trials and are eager for education and information about the trial process, the safety of the investigational product, and the benefits of trial participation. To better meet patient needs, the patient perspective should be incorporated in the very early stages of clinical trial protocol development, and patients should be respected as an integral part of the clinical trial process. PSC patients can also play an important role in advancing PSC clinical trials by, for example, contributing to efforts to develop a PSC-specific patient-reported outcome tool and surrogate markers of clinical endpoints.

• **PSC Partners is ready to help facilitate and expedite research in partnership with industry.** PSC Partners can help with study recruitment through the PSC Partners Patient Registry and can help to identify potential barriers to recruitment and retention. PSC Partners can help educate patients about the trial process, foster trust between patients and researchers, and disseminate clinical trial information via social media platforms and other venues. PSC Partners is also actively studying ways of facilitating development of a robust, regulatory-grade natural history database to support clinical trials.

• **Considerations for PSC clinical trials:**
  o Embrace telehealth services to expand the reach of PSC clinical trials and reduce the burden of participation. The COVID-19 pandemic has revealed the power and potential of telehealth services. PSC Partners encourages clinical researchers to leverage telemedicine, home health visits, electronic informed consent, home drug delivery, and home-based surveys to engage more PSC patients in clinical trials.
  o Reconsider the need for liver biopsies in clinical trials. The increased sensitivity of imaging technologies can hopefully reduce the need for invasive, risky, and often inconclusive liver biopsy procedures.
  o Identify validated surrogate endpoints for PSC clinical trials (and recognize that normalized serum alkaline phosphatase levels do not necessarily correlate with improved quality of life).
  o Develop clinical endpoints that focus on treatment outcomes of importance to patients and on patient survival. Create validated, PSC-specific, patient-reported outcome measures for clinical trials, and include patient involvement in all stages of the tool development process.
Design trials with expanded inclusion criteria. Many patients are willing, but ineligible to participate in a PSC clinical trial (e.g., because they are taking ursodiol).

Consider creative approaches to collecting pediatric clinical trial data (e.g., including teenage PSC patients in adult clinical trials, incorporating a pediatric pharmacokinetics/pharmacodynamics (PK/PD) sub-study into adult studies).

The full-length Voice of the Patient meeting report, recorded webcast, and full set of comments submitted live and during the open comment period for this externally-led PFDD meeting are available on the PSC Partners Seeking a Cure website at https://pscpartners.org/about/the-disease/pfdd-meeting.html. Note that this report does not represent any consensus among participants or the broader population of those living with PSC and does not include all possible perspectives.

THE BETRAYAL IS WITHIN ME

A Poem by a PSC Patient

How do you escape
How do you win
When the battle
is fought within
Battle lines were drawn
Without my being aware
With the intention to destroy
To take without care

(This is a portion of the poem.)